Filter Results

Clinical Studies

Open

Contact Us for the Latest Status

  • A First-in-Human, Open-Label, Dose Escalation And Expansion Trial Of BTX-9341 In Participants With Advanced And/or Metastatic Breast Cancer Jacksonville, Fla.

    The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where participants will receive the dose of BTX-9341 selected in Part A + fulvestrant.

Closed for Enrollment

.